CAPR - Capricor Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$50.00
DETAILS
HIGH:
$62.00
LOW:
$38.00
MEDIAN:
$50.00
CONSENSUS:
$50.00
UPSIDE:
152.14%
About Capricor Therapeutics, Inc. (https://www.capricor.com)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | 1986 | $584,750 USD |
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | 1963 | $580,645 USD |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary | 1953 | $500,718 USD |
| Frank Isaac Litvack FACC | Executive Chairman of the Board | 1956 | $120,000 USD |
| Catherine Lee Kelleher | Consultant | – | – |
| Kristi A. H. Elliott | Chief Operating & Science Officer | – | – |
| Mark Awadalla | Chief Development Officer | – | – |
| Michael Maurer | Chief Commercial Officer | – | – |
| Micheal Binks | Chief Medical Officer | – | – |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | – | – |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | – | – |